Factors involved in prolongation of the terminal disposition phase of SN-38: Clinical and experimental studies

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3451-3458

  Kehrer, D F S ^a   Yamamoto, W ^a   Verweij, J ^a   De Jonge, M J A ^a   De Bruijn, P ^a   Sparreboom, A ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BETA GLUCURONIDASE; BILIRUBIN; CARBOXYLESTERASE; CYTOCHROME P450 3A; IRINOTECAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG OXIDATION; DRUG TRANSPORT; FEMALE; HUMAN; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOTRANSFORMATION; CACO-2 CELLS; CAMPTOTHECIN; CARBOXYLIC ESTER HYDROLASES; COLORECTAL NEOPLASMS; FECES; FEMALE; GLUCURONIDASE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION;

EID: 0033822868     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
2. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
3. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
4. CPT-11 converting enzyme from rat serum: Purification and some properties
5. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase
6. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice beating human neuroblastoma xenografts
7. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11
8. Metabolism of irinotecan to SN-38 in a tumor-isolated tumor model
9. CPT-11 converting carboxylesterase and topisomerase I activities in tumour and normal colon and liver tissues
10. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
11. Glucuronidation of 7-ethyl-10-hydroxycampto-thecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus
12. Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecine derivative irinotecan
13. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes
14. Irinotecan (CPT-11) metabolites in human bile and urine
15. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions
16. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
17. Identification of a new metabolite of CPT-11 (irinotecan). Pharmacological properties and activation to SN-38
18. Irinotecan (CPT-11) metabolism and disposition in cancer patients
19. 14C]CPT-11 in patients with advanced solid tumor malignancy
20. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces
21. Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography
22. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials
23. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
24. Assay of β-glucuronidase in bile following ion-pair extraction of pigments and bile acids
25. Linearized colorimetric assay for Cremophor EL: Application to pharmacokinetics after 1-hour paclitaxel infusions
26. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
27. Human plasma irinotecan carboxylesterase converting enzyme activity in patients receiving infusional irinotecan
28. Applications of the Caco-2 model in the design and development of orally active drugs: Elucidation of biochemical and physical barriers posed by the intestinal epithelium
29. Human jejunal effective permeability and its correlation with preclinical drug absorption models
30. Gastrointestinal absorption of drugs: Methods and studies
31. Identification of metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion
32. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin
33. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes
34. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man
35. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: Interaction between the two biochemical barriers to intestinal transport
36. 3
37. The role of β-glucuronidase in drug disposition and drug targeting in humans
38. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse
39. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats
40. Pharmacokinetics of irinotecan (CPT-11) in patients treated with neomycin to diminish β-glucuronidase activity in the intestines
41. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit carboxylesterase
42. Comparison of the efficiency of CPT-11 activation by a rabbit and a human carboxylesterase for use in enzyme/prodrug therapy (Abstract)
43. Bilirubin (bil) and SN-38 metabolism: Pharmacodynamics of CPT-11 toxicity
44. Severe CPT-11 toxicity in patients with Gilberts syndrome: Two case reports
45. Phase I and pharmacokinetic (PK) study of irinotecan (CPT-11) in cancer patients (pts) with hepatic dysfunction
46. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients
47. In vitro protein binding of CPT-11 metabolites SN-38, SN-38 glucuronide (SN-38G), and APC and possible displacement by commonly used comedications
48. Oral topotecan: Bioavailability and effect of food co-administration